RecruitingPhase 2NCT03990896

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

Sponsor

Massachusetts General Hospital

Enrollment

30 participants

Start Date

Nov 18, 2021

Study Type

INTERVENTIONAL

Conditions

Breast Cancer

Summary

This research is to evaluate the effectiveness of Talazoparib as a potential treatment for metastatic breast cancer with a BRCA 1 or BRCA 2 mutation.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests talazoparib — a drug that targets cells with BRCA gene mutations — in patients with metastatic breast cancer whose tumors have a somatic (acquired, not inherited) BRCA1 or BRCA2 mutation detected in circulating tumor DNA from a blood test. **You may be eligible if...** - You have metastatic breast cancer - Your tumor has a confirmed harmful somatic BRCA1 or BRCA2 mutation on a certified blood-based DNA test (such as Guardant360 or Foundation One) - Your cancer is triple-negative, ER+/HER2-, or HER2+ breast cancer **You may NOT be eligible if...** - You have an inherited (germline) BRCA mutation rather than a somatic one - Your mutation is a variant of unknown significance (VUS) only - You have already received a PARP inhibitor - Your cancer subtype does not meet study criteria Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTalazoparib

Talazoparib is a study drug that inhibits (stops) the normal activity of certain proteins called "poly (ADP-ribose) polymerases" also called "PARPs". PARPs are proteins (made from genes which are part of DNA) that are found in all normal and cancer cells that are involved in the repair of DNA. PARPs are needed to repair mistakes that can happen in DNA when cells divide. If the mistakes are not repaired, the defective cell will usually die and be replaced. Cells with mistakes in their DNA that do not die can become cancer cells.